Hit enter to search or ESC to close
“Over the previous decade now we have reworked the US enterprise from a largely retail particular person life and annuities enterprise to a high-performing market main advantages enterprise,” stated Dan Fishbein, president, Solar Life Monetary US. “The DentaQuest acquisition continues this evolution, altering the footprint of our enterprise within the US into a bigger, extra healthcare-focused group, now with greater than 70% of our advantages income coming from healthcare.
“These modifications have transitioned Solar Life US from a capital-intensive to a capital-light enterprise with sturdy money stream technology; from companies with long-term threat profiles to largely short-term threat and fee-based companies; from slow-growth markets to larger development markets; and from return on fairness (ROE) within the single digits to a return on tangible fairness within the excessive teenagers.”
Learn subsequent: Solar Life experiences blended monetary leads to Q2
Headquartered in Boston and based in 2001, DentaQuest introduced greater than 33 million members in 36 states and greater than 2,400 staff throughout to Solar Life US. On the time of acquisition, it was the biggest supplier of US Medicaid dental advantages, with rising Medicare Benefit, business, and US Inexpensive Care Act (ACA) trade companies.
The management workforce for the mixed dental advantages enterprise below Solar Life US consists of a mix of DentaQuest and Solar Life leaders, all of whom are targeted on development methods, income synergies, and optimizing efficiency, in keeping with Fishbein.
“We’re approaching integration with nice care and our objective is to comprehend the complete potential of the transaction for all our stakeholders, together with offering enhanced choices for purchasers, delivering our accretion and value financial savings targets for shareholders, creating new alternatives for our staff, and delivering a constructive integration expertise for all,” he defined.
“We’ve got a robust observe file of efficiently integrating group advantages companies, whereas minimizing disruption for our purchasers. Most of the leaders who managed the Assurant integration are concerned within the DentaQuest integration. We’re targeted on integration actions that may assist our run price price financial savings goal of $60 million by 2024. We’re off to a robust begin with a totally built-in management workforce, engaged staff, and an in depth plan for the remaining steps.”
Solar Life US introduced its second quarter 2022 monetary outcomes on August 3, by which it reported insurance coverage gross sales of $213 million, up 12% year-over-year, pushed by larger dental and medical stop-loss gross sales. The enterprise reported web revenue of $213 million, up by 36%, or $56 million, from the prior 12 months interval, however partially offset by prices associated to the DentaQuest acquisition.
Learn extra: Met Life trumps analyst expectations on sturdy premiums and costs
When Solar Life first introduced the DentaQuest deal, it gave an accretion projection of a further 42 foundation factors to underlying ROE in 2022 on an annualized foundation. In 2024, upon realization of expense synergies, Solar Life expects the acquisition so as to add roughly 50 foundation factors to underlying ROE.
“The underlying earnings for DentaQuest within the one month [June 2022] was $10 million,” stated Fishbein. “We’re nonetheless assured within the accretion projections that we made after we introduced the transaction, and positively, the leads to June would assist that. We did see larger margins in June than maybe we anticipated, and just a little decrease revenues, however the larger margins greater than made up for the small variance in revenues. General […] this primary month offers us confidence in our prior projections.”
Fishbein stated he’s excited concerning the future at Solar Life US, including: “We now have 4 sturdy companies with market main positions in dental and stop-loss, and a high 10 worker advantages enterprise. Though latest outcomes have been considerably masked by COVID impacts, as soon as this subsides, we stay assured in reaching our medium-term targets for the US, together with 10% or extra earnings development for our advantages companies.”
About the author
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.